HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Cornelius M. Dyke George W. Maier Jerrold H. Levy Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dyke, C. M. Articles by Levy, J. H. Search for Related Content PubMed PubMed Citation Articles by Dyke, C. M. Articles by Levy, J. H. Related Collections Extracorporeal circulation

Ann Thorac Surg 2005;80:299-303
© 2005 The Society of Thoracic Surgeons

---

New technology

Preemptive Use of Bivalirudin for Urgent On-Pump Coronary Artery Bypass Grafting in Patients With Potential Heparin-Induced Thrombocytopenia

^a Department of Surgery and Anesthesiology, Gaston Memorial Hospital, Gastonia, North Carolina
^b Department of Anesthesia, Deutsches Herzzentrum, Berlin, Germany
^c Department of Cardiothoracic Anesthesiology, Emory University School of Medicine, Atlanta, Georgia

Accepted for publication August 19, 2004.

^_* Address reprint requests to Dr Dyke, Sanger Clinic-Gastonia, Suite 200, 2555 Court Dr, Gastonia, NC 28054 (Email: cdyke{at}sanger-clinic.com).

PURPOSE: The use of heparin in patients with heparin-induced thrombocytopenia (HIT) may result in severe complications or death. The diagnosis of HIT is frequently uncertain, however. Alternative anticoagulants in at-risk patients undergoing cardiac surgery with cardiopulmonary bypass remain problematic. The novel short-acting, direct-thrombin inhibitor bivalirudin is the only alternative to heparin/protamine being used in elective non-HIT patients during CPB.

DESCRIPTION: Four patients with severe thrombocytopenia after heparin exposure and suspected acute HIT underwent on-pump coronary artery bypass grafting surgery with preemptive use of bivalirudin. A continuous bivalirudin infusion was used during cardiopulmonary bypass, and activated clotting times were used to monitor anticoagulation.

EVALUATION: Anticoagulation with bivalirudin during cardiopulmonary bypass was effective and uncomplicated. Duration of operation was not prolonged, and perioperative blood loss and transfusion rates were acceptable. Activated clotting times were helpful for monitoring anticoagulation in these patients.

CONCLUSIONS: These data provide further evidence of the feasibility of bivalirudin for anticoagulation during on-pump coronary artery bypass graft surgery in urgent clinical situations.

This article has been cited by other articles:

				J. H. Levy, K. A. Tanaka, and J. M. Bailey Cardiac Surgical Pharmacology Card. Surg. Adult, January 1, 2008; 3(2008): 77 - 110. [Full Text]

				J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]

				D. C. Kress, S. Aronson, M. L. McDonald, M. I. Malik, A. B. Divgi, A. J. Tector, F. X. Downey III, A. J. Anderson, M. Stone, and C. Clancy Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgical Outcomes Ann. Thorac. Surg., May 1, 2007; 83(5): 1737 - 1743. [Abstract] [Full Text] [PDF]

				A. Koster, C. M. Dyke, G. Aldea, N. G. Smedira, H. L. McCarthy II, S. Aronson, R. Hetzer, E. Avery, B. Spiess, and A. M. Lincoff Bivalirudin During Cardiopulmonary Bypass in Patients With Previous or Acute Heparin-Induced Thrombocytopenia and Heparin Antibodies: Results of the CHOOSE-ON Trial Ann. Thorac. Surg., February 1, 2007; 83(2): 572 - 577. [Abstract] [Full Text] [PDF]